Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00563810
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- Men aged 18 to 45 years inclusive on study day 1.
- Elderly men and women aged 65 to 80 years inclusive on study day 1.
- Women must be postmenopausal for > or = 1 year (with estradiol < 25 pg/mL and an FSH > 40 mIU/mL).
- Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, clinical laboratory test results, and 12-leave electrocardiogram.
- Elderly subjects may have stable, nonclinically significant abnormalities on physical examination, and laboratory evaluation.
- Non-smoker.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To assess safety and tolerability.
- Secondary Outcome Measures
Name Time Method